A Phase 2a, Prospective, Randomized, Double-Blinded, Placebo-Controlled Trial of DaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis
Latest Information Update: 19 Sep 2023
Price :
$35 *
At a glance
- Drugs Daxibotulinumtoxin A (Primary)
- Indications Plantar fasciitis
- Focus Proof of concept; Therapeutic Use
- Sponsors Revance Therapeutics
- 30 Jun 2020 According to a Revance Therapeutics media release, the company look forward to announcing the readouts in the coming months.
- 19 Apr 2018 Results published in the Revance Therapeutics Media Release
- 19 Apr 2018 According to a Revance Therapeutics ,Status changed from active, no longer recruiting to completed.